Signage is seen outside the Blackstone Group headquarters in New York City, U.S., January 18, 2023.
Anthos, which does not generate any revenue because its products have not yet hit the market, could be worth several billion dollars in a potential sale, significantly more than the $250 million that Blackstone invested when it founded Anthos in 2019, the sources said.
The company's anticoagulants have made significant progress in late-stage clinical trials, the sources added.
Blackstone is working with investment bankers to explore a sale of Anthos, the sources said, cautioning that no deal is certain and requesting anonymity because the matter is confidential.
Anthos has licensed from Novartis an antibody used in the development of its blood thinners and granted it a minority stake.
Persons:
Blackstone, Anthos, Bayer, Eliquis, David Carnevali, Leslie Adler
Organizations:
Blackstone Group, REUTERS, Blackstone Inc, Anthos Therapeutics, Novartis AG, Novartis, Myers Squibb, Alnylam Pharmaceuticals, Thomson
Locations:
New York City, U.S, Cambridge , Massachusetts, Anthos, Bristol, German, New York